{"schema_version":"secwatch.filing_event.v1","accession":"0000719135-24-000024","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.765667+00:00","generated_at":"2026-06-02T07:34:18.696138+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apyx Medical Q1 revenue $10.2M (-16% YoY); net loss $7.6M; Chairman retires","bullets":["Total revenue $10.2M (-16% YoY); Advanced Energy $7.5M (-23%); OEM $2.8M (+14%).","Net loss $7.6M ($0.22/share) vs $3.5M ($0.10) loss a year ago; Adjusted EBITDA loss $5.3M vs $4.0M.","Reaffirms FY2024 guidance: revenue $49.7M-$52.9M; net loss expected $24.3M-$26.5M.","Chairman Andrew Makrides retires after 42 years; Stavros Vizirgianakis elected Chairman effective May 7, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000719135-24-000024","json":"https://secwatch.observer/filing/0000719135-24-000024.json","markdown":"https://secwatch.observer/filing/0000719135-24-000024.md","text":"https://secwatch.observer/filing/0000719135-24-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000024/0000719135-24-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000024/apyx-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:34:18.696138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09dc3749e98ec1e898be19da3ad1368d2079fec8","claim":"Apyx Medical Corp reported first quarter ended March 31, 2024 results: revenue $10.2 million, net income $7.6 million, EPS $0.22 per share. Guidance reaffirmed.","evidence_excerpt":"quarter ended March 31, 2024; and reaffirmed its financial expectations for the full year ending December 31, 2024 First Quarter 2024 Financial Summary : • Total revenue of $10.2 million, a decrease of 16% year-over-year. ◦ Advanced Energy revenue of $7.5 million, a decrease of 23% year-over-year. ◦ OEM revenue of $2.8 million, an increase of 14% year-over-year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000024/0000719135-24-000024-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$10.2 million"},{"label":"Net income","value":"$7.6 million"},{"label":"EPS","value":"$0.22 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"212253dde1be04d8d05d2074deeb90ba2b45bdfc","claim":"Apyx Medical Corp reported year ending December 31, 2024 results: revenue $49.7 million to $52.9 million. Guidance reaffirmed.","evidence_excerpt":"respectively . Full Year 2024 Financial Outlook: The Company is reaffirming its financial guidance for the year ending December 31, 2024: • Total revenue in the range of $49.7 million to $52.9 million, representing a decrease of approximately 5% to growth of approximately 1% year-over-year, compared to total revenue of $52.3 million for the year ended December","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000024/0000719135-24-000024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ending December 31, 2024"},{"label":"Revenue","value":"$49.7 million to $52.9 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}